[Skip to Navigation]
Sign In
Correction
March 2018

Omitted Conflict of Interest Disclosures

JAMA Cardiol. 2018;3(3):266. doi:10.1001/jamacardio.2017.5142

In the Reply Letter titled “Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan—Reply,”1 published online March 22, 2017, and in the July 2017 issue of JAMA Cardiology, the author disclosed conflicts of interest that were inadvertently omitted. The Conflict of Interest Disclosures section should read as follows: “The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Packer has received personal fees from Amgen, Admittance, Bayer, Boehringer Ingelheim, Celyad, Daiichi Sankyo, Ferring, GlaxoSmithKline, Novartis, Relypsa, Sanofi, Takeda, and ZS Pharma.” This article was corrected online.

References
1.
Packer  M.  Let us not forget the long-term safety concerns of sacubitril/valsartan—reply.  JAMA Cardiol. 2017;2(7):819.PubMedGoogle ScholarCrossref
×